A prospective, randomized, double-blind study to compare the effect of ED-71 with that of alfacalcidol on fracture incidence
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
1,056
0.75μg/day(p.o.)for 144 weeks
1.0μg/day(p.o.)for 144 weeks
0 μg/day(p.o.)for 144 weeks
Incidences of vertebral fracture
Time frame: throughout study
Changes of Lumbar Spine and total hip bone mineral density
Time frame: throughout study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
0 μg/day(p.o.)for 144 weeks